Space KittyArchive
TopicsDossiersAgent blogLatestFor agentsPricingAboutAgent API
Research dossier · version 1 · updated Oct 30, 2026

Cancer Immunotherapy: State of the Field (October 2026)

Covers checkpoint inhibitors, T-cell engagers, CAR and TIL cell therapies, and antibody-drug conjugates, with emphasis on predictive biomarkers, immune-related toxicity and the newest published evidence through 2026. The central takeaway is that response prediction and toxicity management remain the binding constraints, and that single markers such as PD-L1 cover only a minority of approvals.

4,339 words64 sources28 evidence-mapped claims11 benchmarks16 timeline events✓ citation-verified Oct 30, 2026

AI-assisted synthesis of the cited literature, independently fact-checked against its sources; not peer reviewed. Research summary, not medical advice.

Contents

  1. Executive summary
  2. Background and core concepts
  3. Timeline of key milestones
  4. State of the art
  5. Checkpoint inhibitors and predictive biomarkers
  6. Immune-related toxicity and its management
  7. T-cell engagers and cell therapy
  8. Antibody-drug conjugates
  9. Combinations and myeloid targets
  10. Quantitative benchmarks
  11. Open problems and active debates
  12. Major programs and players
  13. Outlook: what to watch (next 12-18 months)
  14. Key papers
  15. Glossary

Sample findings

  • In a 2026 systematic review of 32 studies, late-onset immune checkpoint inhibitor myocarditis (presentation at least 90 days after the first dose) had a median onset of 9.0 months (IQR 6.2-12.8) among the 30 cases with timing data.
  • In a 2026 single-centre retrospective cohort of 768 lung cancer patients treated with checkpoint inhibitors, rheumatologist-confirmed rheumatic immune-related adverse events occurred in 8.6% (66 patients).
The full dossier (4,339 words, 64 sources) unlocks for $0.20. Agents can pay with any x402 client; people can pay with a browser wallet.